CPT-11 and its effects on colon cancer
Author Information
Author(s): Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Frétigny E, Selves J, Chatelut E, Bugat R, Canal R
Primary Institution: Groupe de Pharmacologie Clinique et Expérimentale, Institut Claudius Regaud
Hypothesis
The study evaluates the activities of CPT-11 converting carboxylesterase and topoisomerase I in colorectal tumors and normal tissues.
Conclusion
CPT-CE and topo I activities vary widely in colorectal tumors and adjacent normal tissues, with potential implications for chemotherapy response.
Supporting Evidence
- CPT-11 is activated by carboxylesterases to the active metabolite SN-38.
- CPT-CE activity was only two to threefold lower in primary tumors compared to normal liver.
- Topoisomerase I levels in tumors varied widely, with some patients showing very high activity.
- An inverse correlation was found between topo I activity and clinical stage of disease.
Takeaway
The study looked at how a cancer drug is processed in tumors and normal tissues, finding that the drug might work differently in each.
Methodology
The activities of CPT-CE and topo I were evaluated in 53 colorectal tumors and 8 liver metastases.
Participant Demographics
Patients with colorectal carcinomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website